Skip to main content

Table 6 The clinical trials exploring the efficacy of α-PD-1/PD-L1 combined with targeted therapy (except for angiogenesis inhibitor)

From: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Clinical trial

Phase

α-PD-1/PD-L1

Targeted therapy (Target)

Cancer type

Primary outcome measures

NCT01454102

1

Nivolumab

Erlotinib (EGFR)

NSCLC

Safety

NCT02013219

1

Atezolizumab

Erlotinib (EGFR)

NSCLC

Safety, RP2D

NCT02143466

1

Durvalumab

Osimertinib (EGFR)

NSCLC

Safety

NCT02454933

3

Durvalumab

Osimertinib (EGFR)

NSCLC

Safety

NCT02574078

1/2

Nivolumab

Crizotinib (Met/ALK/ROS)

NSCLC

Safety

NCT02511184

1

Pembrolizumab

Crizotinib (Met/ALK/ROS)

NSCLC

Safety

NCT02013219

1

Atezolizumab

Alectinib (ALK/ FLT3/RET)

NSCLC

Safety, RP2D

NCT02584634

2

Avelumab

Crizotinib (Met/ALK/ROS)

NSCLC

ORR, Safety

NCT02660034

1

Tislelizumab

Pamiparib (PARP)

Solid tumor

Safety, ORR, PFS, DOR, DCR, CBR, OS

NCT04475939

3

Pembrolizumab

Niraparib (PARP)

NSCLC

PFS, OS

NCT02657889

1/2

Pembrolizumab

Niraparib (PARP)

TNBC, Ovarian cancer

Safety, ORR

NCT02734004

2

Durvalumab

Olaparib (PARP)

Ovarian cancer

DCR, ORR, Safety

NCT02484404

1/2

Durvalumab

Olaparib (PARP)

Solid tumor

RP2D, ORR

NCT01988896

1

Atezolizumab

Cobimetinib (MEK)

Solid tumor

Safety, RP2D

NCT02322814

2

Atezolizumab

Cobimetinib (MEK)

TNBC

PFS, ORR

NCT02788279

3

Atezolizumab

Cobimetinib (MEK)

Colorectal cancer

OS

NCT03600883

1/2

Unspecified

AMG 510 (KRAS)

KRAS p.G12C mutant solid tumor

Safety

NCT02972034

1

Pembrolizumab

MK-8353 (ERK)

Solid tumor

Safety

NCT02967692

3

PDR001

Dabrafenib (RAF) and Trametinib (MEK)

Melanoma

Safety, PFS

NCT04017650

1/2

Nivolumab

Encorafenib (RAF) and Cetuximab (EGFR)

Colorectal cancer

Best radiographic response; Safety

NCT03502733

1

Nivolumab

Copanlisib (PI3K)

Solid tumor and lymphoma

Safety

NCT03395899

2

Atezolizumab

Ipatasertib (AKT)

Breast cancer

2-fold increase in GzmB+CD8+ T cell

NCT02393248

1/2

Pembrolizumab

Pemigatinib (FGFR)

Solid tumor

Maximum tolerated dose, Pharmacodynamics

NCT03123055

1/2

Pembrolizumab

B-701 (FGFR)

Urothelial cell carcinoma

Safety, ORR

NCT02819596

2

Durvalumab

Savolitinib (c-MET)

Renal cell carcinoma

Safety, ORR

NCT02779751

1

Pembrolizumab

Abemaciclib (CDK4/6)

NSCLC, Breast cancer

Safety

NCT04000529

1

Spartalizumab

TNO155 (SHP-2)

Solid tumor

Safety

  1. Abbreviations: NSCLC non-small cell lung cancer, PFS progression-free survival, OS overall survival, RP2D recommended phase 2 dose, DOR duration of response, DCR disease control rate, CBR clinical benefit rate